New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
09:25 EDTNBIX, NBIX, NBIXPiper Jaffray's biotech research team holds analyst/industry conference call
Analyst Research Team, along with Dr. Joseph Jankovic, Professor of Neurology at Baylor College of Medicine, discusses current therapies and the role of selective VMAT-2 inhibitors for tardive dyskinesia and other movement disorders, along with Neurocrine's NBI-98854, on an Analyst/Industry conference call to be held on April 5 at 10 am.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:02 EDTNBIXNeurocrine announces oral presentation of NBI-77860 trial data
Neurocrine Biosciences announced that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting. The ENDO 2015 meeting will be held in San Diego from March 5-8.
07:52 EDTNBIXNeurocrine price target raised to $39 from $32 at Jefferies
Subscribe for More Information
January 16, 2015
14:31 EDTNBIXNeurocrine confirms FDA grants orphan status to NBI-77860
Subscribe for More Information
12:05 EDTNBIXNeurocrine granted orphan status for CAH treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use